← PCSK9 inhibitors × cardiovascular events

SynthesisHerz2019

Effects of monoclonal antibodies against PCSK9 on clinical cardiovascular events : A meta-analysis of randomized controlled trials.

Y Zhu et al.PubMed ↗Publisher ↗

  • Monoclonal antibodies against PCSK9looks good hereFewer positively adjudicated cardiovascular events, lower coronary revascularization, lower MI.Randomised, large.

What the trial testedrandomised · 67,934 people · 2019

Randomised comparison

Reduced positively adjudicated cardiovascular events

−13%−19% to −7%

Monoclonal antibodies against PCSK9

Bigger than 2 in 10 for cardiovascular events

As reported

RR 0.87, 95% CI 0.81–0.93

Randomised comparison

Lowered coronary revascularization

−19%−25% to −12%

Monoclonal antibodies against PCSK9

Bigger than 4 in 10 for cardiovascular events

As reported

RR 0.81, 95% CI 0.75–0.88

Randomised comparison

Lowered MI

−22%−29% to −14%

Monoclonal antibodies against PCSK9

Bigger than 5 in 10 for cardiovascular events

As reported

RR 0.78, 95% CI 0.71–0.86

Randomised comparison

Reduced stroke

−24%−35% to −11%

Monoclonal antibodies against PCSK9

Bigger than 6 in 10 for cardiovascular events

As reported

RR 0.76, 95% CI 0.65–0.89

Who was studied, and how

67,934people with cardiovascular disease, in this paper

The trial randomly assignedassigned by chance

Monoclonal antibodies against PCSK9
the rest

Reduced positively adjudicated cardiovascular events−13%

Lowered coronary revascularization−19%

Lowered MI−22%

randomised

the abstract, start to end

… events (relative risk [RR] = 0.87; 95% confidence interval [CI] = 0.81-0.93; z = 4.03; p = 0.000), MI (RR = 0.78; 95% CI = 0.71-0.86; z = 4.96; p = 0.000), coronary revascularization (RR = 0.81, 95% CI = 0.75-0.88; z = 4.93; p = 0.000), and stroke (RR = 0.76, 95% CI = 0.65-0.89; z = 3.47; …

← favours treatmentfavours comparator →
could be chance
Positively adjudicated cardiovascular eventsMonoclonal antibodies against PCSK9
RR 0.870.81–0.93
Coronary revascularizationMonoclonal antibodies against PCSK9
RR 0.810.75–0.88
MIMonoclonal antibodies against PCSK9
RR 0.780.71–0.86
StrokeMonoclonal antibodies against PCSK9
RR 0.760.65–0.89
PCSK9 inhibitorsCardiovascular events
1 / 4

2 papers cite it

2018
2019
2020
2021
2022
2023
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 29116337